Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like P*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000101 Par Pharmaceutical 09/30/2022 42023010501 BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL 09/19/2022 15.01 85.92 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000101 Par Pharmaceutical 09/30/2022 42023011925 TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl 09/19/2022 203.95 1167.61 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000053 Paratek Pharmaceuticals, Inc. 03/31/2022 71715000227 Nuzyra Oral Tablet 150 MG 30 pack 01/01/2022 204.30 7014.41 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000053 Paratek Pharmaceuticals, Inc. 09/30/2022 71715000227 Nuzyra Oral Tablet 150 MG 30 pack 07/01/2022 210.43 7224.84 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000053 Paratek Pharmaceuticals, Inc. 03/31/2022 71715000221 Nuzyra Oral Tablet 150 MG 6 pack 01/01/2022 40.86 1402.88 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000053 Paratek Pharmaceuticals, Inc. 09/30/2022 71715000221 Nuzyra Oral Tablet 150 MG 6 pack 07/01/2022 42.09 1444.95 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000006 Pfizer 03/31/2022 00409592101 AMINOPHYLLINE (aminophylline), 250 mg/10 mL, VIAL (ML), 1 01/01/2022 31.25 343.77 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409592201 AMINOPHYLLINE (aminophylline), 500 mg/20 mL, VIAL (ML), 1 01/01/2022 20.11 221.25 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009722402 ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5 01/01/2022 2862.89 14314.46 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409963005 ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1 01/01/2022 13.92 153.08 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409491134 ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 01/01/2022 10.42 114.62 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409491034 ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 01/01/2022 9.10 100.05 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409163010 ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 01/01/2022 5.80 63.75 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409963005 Atropine Sulfate Injection Rx, 0.05 mg/mL (0.25 mg/5 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 15.31 168.39 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409491034 Atropine Sulfate Injection Rx, 0.1 mg/mL (0.5 mg/5 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 07/01/2022 10.01 110.06 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409163010 Atropine Sulfate Injection Rx, 0.1 mg/mL (1 mg/10 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 6.38 70.13 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409491134 Atropine Sulfate Injection Rx, 0.1 mg/mL (1 mg/10 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 07/01/2022 11.46 126.08 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409196612 Bacteriostatic 0.9% Sodium Chloride Injection Rx, 10 mL (0.9%) Multiple Dose LifeShield™ Plastic Fliptop Vial, 25 07/01/2022 4.38 48.18 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409397703 Bacteriostatic Water Injection Rx, 30 mL Multiple Dose Plastic Fliptop Vial, 25 07/01/2022 3.73 41.00 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 60793060110 BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 01/01/2022 137.23 1509.57 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 60793060010 BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 01/01/2022 137.23 1509.57 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 60793060210 BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1 01/01/2022 137.23 1509.57 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793060210 Bicillin C-R 900/300® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1" needle) Pediatric, 10 07/01/2022 150.96 1660.53 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793060110 Bicillin C-R® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1" needle) Pediatric, 10 07/01/2022 150.96 1660.53 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793060010 Bicillin C-R® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 10 07/01/2022 150.96 1660.53 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 60793070110 BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1 01/01/2022 172.16 1893.74 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 60793070210 BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1 01/01/2022 352.78 3880.58 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 60793070010 BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1 01/01/2022 99.40 1093.41 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793070010 Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 1 mL Pre-Filled Syringe (21 gauge x 1" needle) Pediatric, 10 07/01/2022 109.34 1202.75 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793070110 Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 2 mL Pre-Filled Syringe (21 gauge x 1-1/2" needle), 10 07/01/2022 189.37 2083.11 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793070210 Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 4 mL Pre-Filled Syringe (18 gauge x 1-1/2" needle), 10 07/01/2022 388.06 4268.64 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069013501 BOSULIF (bosutinib), 100 mg, TABLET, 1 01/01/2022 905.11 17361.70 04/01/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069019301 BOSULIF (bosutinib), 400 mg, TABLET, 1 01/01/2022 905.11 17361.70 04/01/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069013601 BOSULIF (bosutinib), 500 mg, TABLET, 1 01/01/2022 905.11 17361.70 04/01/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409162301 Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10 07/01/2022 4.61 50.67 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409162601 Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10 07/01/2022 5.63 61.97 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409162602 Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10 07/01/2022 7.93 87.25 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409492834 CALCIUM CHLORIDE (calcium chloride), 100 mg/mL (10 %), SYRINGE (ML), 1 01/01/2022 9.65 106.15 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409163110 Calcium Chloride Injection Rx, 100 mg/mL (1 g/10 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 7.84 86.20 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409492834 Calcium Chloride Injection Rx, 100 mg/mL (1 g/10 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 07/01/2022 10.62 116.77 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409337301 Corlopam® (fenoldopam mesylate) Injection Rx, 10 mg Single Dose Vial, 1 07/01/2022 41.36 454.95 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409337302 Corlopam® (fenoldopam mesylate) Injection Rx, 20 mg Single Dose Vial, 1 07/01/2022 82.72 909.91 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069153130 DAURISMO (glasdegib maleate), 100 mg, TABLET, 1 01/01/2022 1026.29 19686.10 01/30/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2031 upon the grant of the patent term extension application.
Rx0000006 Pfizer 03/31/2022 00069029860 DAURISMO (glasdegib maleate), 25 mg, TABLET, 1 01/01/2022 1026.29 19686.10 01/30/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2031 upon the grant of the patent term extension application.
Rx0000006 Pfizer 03/31/2022 00409125502 DEMEROL (meperidine HCl/PF), 100 mg/2 mL, AMPUL (ML), 1 01/01/2022 5.51 115.78 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409118130 Demerol™ (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1 07/01/2022 4.06 85.32 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009027101 DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1 01/01/2022 11.58 127.35 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00009027101 Depo-Estradiol® (estradiol cypionate) Sterile Solution Rx, 5 mg/mL 5 mL Vial, 1 07/01/2022 12.74 140.09 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409177510 DEXTROSE IN WATER (dextrose 25 % in water), 25 %, SYRINGE (ML), 1 01/01/2022 9.60 105.64 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409490234 DEXTROSE IN WATER (dextrose 50 % in water), 50 %, SYRINGE (ML), 1 01/01/2022 9.41 103.49 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409751716 DEXTROSE IN WATER (dextrose 50 % in water), 50 %, SYRINGE (ML), 1 01/01/2022 9.20 101.22 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409664802 DEXTROSE IN WATER (dextrose 50 % in water), 50 %, VIAL (ML), 1 01/01/2022 7.76 85.39 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409751716 Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) Ansyr™ II Plastic Syringe (side/side), 10 07/01/2022 10.12 111.34 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409490234 Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) LifeShield™ Abboject™ Glass Syringe (18 G x 1 1/2"), 10 07/01/2022 10.35 113.84 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409664802 Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) Single Dose Glass Fliptop Vial, 25 07/01/2022 8.54 93.93 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409710067 Dextrose Injection Rx, 100 mL (5%) ADD-Vantage™ Flexible Container, 50 07/01/2022 13.63 149.92 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409177510 Dextrose Injection Rx, 250 mg/mL (2.5 g/10 mL) (25%) Ansyr™ Plastic Syringe, 10 07/01/2022 10.56 116.20 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409710002 Dextrose Injection Rx, 250 mL (5%) ADD-Vantage™ Flexible Container, 24 07/01/2022 8.68 95.45 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409710066 Dextrose Injection Rx, 50 mL (5%) ADD-Vantage™ Flexible Container, 50 07/01/2022 13.46 148.02 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409910420 DOPAMINE HCL (dopamine HCl), 400 mg/10 mL (40 mg/mL), VIAL (ML), 1 01/01/2022 5.41 59.46 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409493301 Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10 07/01/2022 5.76 63.38 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069021702 Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 07/01/2022 90.73 998.07 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069022002 Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 07/01/2022 113.43 1247.68 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069022302 Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 07/01/2022 136.10 1497.13 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069022802 Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10 07/01/2022 163.32 1796.55 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069019502 Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 07/01/2022 27.96 307.59 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069019602 Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 07/01/2022 45.37 499.04 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069020602 Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 07/01/2022 68.06 748.64 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069023201 Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1 07/01/2022 77.99 857.89 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409163910 FUROSEMIDE (furosemide), 10 mg/mL, SYRINGE (ML), 1 01/01/2022 18.54 203.94 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409963104 FUROSEMIDE (furosemide), 10 mg/mL, SYRINGE (ML), 1 01/01/2022 11.12 122.34 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409163910 Furosemide Injection Rx, 10 mg/mL (100 mg/10 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 20.39 224.33 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409963104 Furosemide Injection Rx, 10 mg/mL (40 mg/4 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 12.23 134.57 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409120703 Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25 07/01/2022 7.04 35.21 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409765062 Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24 07/01/2022 23.32 256.51 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409765162 Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24 07/01/2022 20.17 221.87 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069013703 HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 01/01/2022 0.77 77.74 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069005801 HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 01/01/2022 0.84 84.35 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409272003 HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 01/01/2022 1.92 194.31 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409272001 HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 01/01/2022 0.46 46.40 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409272002 HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 01/01/2022 0.84 84.35 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409272101 HEPARIN SODIUM (heparin sodium,porcine), 10,000 unit/mL, VIAL (ML), 1 01/01/2022 0.81 82.30 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409140212 HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL (1 mL), CARTRIDGE (ML), 1 01/01/2022 1.43 144.74 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069005901 HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1 01/01/2022 2.88 291.24 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409272301 HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1 01/01/2022 0.50 50.49 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069005903 HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1 01/01/2022 1.04 105.06 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409272302 HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML),1 01/01/2022 2.88 291.24 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409131632 HEPARIN SODIUM (heparin sodium,porcine/PF), 5,000 unit/0.5 mL, CARTRIDGE (ML), 1 01/01/2022 4.98 170.84 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409765062 HEPARIN SODIUM IN 0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 1 01/01/2022 1.16 233.19 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409765162 HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 12,500 unit/250 mL, INTRAVENOUS SOLUTION, 1 01/01/2022 1.00 201.70 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409765103 HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/500 mL (50 unit/mL), INTRAVENOUS SOLUTION, 1 01/01/2022 17.58 193.33 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409762003 HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine IN 0.9 % sodium chloride/PF), 1,000 unit/500 mL (2 unit/mL), INTRAVENOUS SOLUTION, 1 01/01/2022 0.98 98.91 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409762059 HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine IN 0.9 % sodium chloride/PF), 2,000 unit/1,000 mL (2 unit/mL), INTRAVENOUS SOLUTION, 1 01/01/2022 0.80 80.78 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409779362 HEPARIN SODIUM-D5W (heparin sodium,porcine/dextrose 5 % in water), 25,000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 1 01/01/2022 2.29 230.99 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409128305 Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (0.5 mg/0.5 mL) iSecure™ Luer Lock Glass Syringe (no needle), 10 07/01/2022 2.85 31.35 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409255201 Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (1 mg/1 mL) Glass Ampul, 10 07/01/2022 2.03 22.37 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069018821 IBRANCE (palbociclib), 100 mg, CAPSULE, 1 01/01/2022 901.96 13973.80 03/05/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069018921 IBRANCE (palbociclib), 125 mg, CAPSULE, 1 01/01/2022 901.96 13973.80 03/05/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069018721 IBRANCE (palbociclib), 75 mg, CAPSULE, 1 01/01/2022 901.96 13973.80 03/05/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069014501 INLYTA (axitinib), 1 mg, TABLET, 1 01/01/2022 1147.36 17775.76 04/29/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069015111 INLYTA (axitinib), 5 mg, TABLET, 1 01/01/2022 1147.36 17775.76 04/29/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409913705 LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 01/01/2022 6.99 76.90 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409490434 LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 01/01/2022 10.16 111.72 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409913705 Lidocaine Hydrochloride Injection Rx, 1% (10 mg/mL) 50 mg/5 mL Ansyr™ Plastic Syringe, 10 07/01/2022 7.69 84.59 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409490434 Lidocaine Hydrochloride Injection Rx, 1% (10 mg/mL) 50 mg/5 mL LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 07/01/2022 11.17 122.89 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409132305 Lidocaine Hydrochloride Injection Rx, 2% (20 mg/mL) 100 mg/5 mL Ansyr™ Plastic Syringe, 10 07/01/2022 3.73 41.04 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409490334 Lidocaine Hydrochloride Injection Rx, 2% (20 mg/mL) 100 mg/5 mL LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 07/01/2022 3.89 42.82 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069023101 LORBRENA (lorlatinib), 100 mg, TABLET, 1 01/01/2022 973.58 18675.11 03/05/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069022701 LORBRENA (lorlatinib), 25 mg, TABLET, 1 01/01/2022 324.53 6225.05 03/05/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409175410 MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1 01/01/2022 19.01 209.12 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409175410 Magnesium Sulfate Injection Rx, 500 mg/mL (5 g/10 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 20.91 230.03 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409259603 MIDAZOLAM HCL (midazolam HCl), 5 mg/mL, VIAL (ML), 1 01/01/2022 0.44 44.44 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409464601 PANCURONIUM BROMIDE (pancuronium bromide), 1 mg/mL, VIAL (ML), 1 01/01/2022 6.81 142.93 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 06/30/2022 00069101102 Panzyga (immune globulin intravenous, human - ifas) 1 g/10 mL Vial, 1 04/01/2022 2.84 193.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 06/30/2022 00069131202 Panzyga (immune globulin intravenous, human - ifas) 10 g/100 mL Vial, 1 04/01/2022 28.40 1930.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 06/30/2022 00069110902 Panzyga (immune globulin intravenous, human - ifas) 2.5 g/25 mL Vial, 1 04/01/2022 7.10 482.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 06/30/2022 00069141502 Panzyga (immune globulin intravenous, human - ifas) 20 g/200 mL Vial, 1 04/01/2022 56.80 3860.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 06/30/2022 00069155802 Panzyga (immune globulin intravenous, human - ifas) 30 g/300 mL Vial, 1 04/01/2022 85.20 5790.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 06/30/2022 00069122402 Panzyga (immune globulin intravenous, human - ifas) 5 g/50 mL Vial, 1 04/01/2022 14.20 965.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069101102 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 1 g/10 mL Vial, 1 07/01/2022 2.90 195.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 12/31/2022 00069101102 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 1 g/10 mL Vial, 1 10/01/2022 2.94 198.84 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069131202 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1 07/01/2022 29.00 1959.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 12/31/2022 00069131202 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1 10/01/2022 29.40 1988.40 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069110902 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1 07/01/2022 7.25 489.75 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 12/31/2022 00069110902 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1 10/01/2022 7.35 497.10 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069141502 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1 07/01/2022 58.00 3918.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 12/31/2022 00069141502 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1 10/01/2022 58.80 3976.80 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069155802 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1 07/01/2022 87.00 5877.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 12/31/2022 00069155802 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1 10/01/2022 88.20 5965.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00069122402 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1 07/01/2022 14.50 979.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 12/31/2022 00069122402 Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1 10/01/2022 14.70 994.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793013010 Penicillin G Procaine Injectable Suspension Rx, 1 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 1 07/01/2022 37.98 417.74 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 60793013110 Penicillin G Procaine Injectable Suspension Rx, 2 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 1 07/01/2022 63.84 702.25 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00005197105 PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (Diphtheria crm) / PF), 0.5 mL, SYRINGE (ML), 1 01/01/2022 15.02 232.76 11/09/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00005197102 PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (Diphtheria crm)/PF), 0.5 mL, SYRINGE (ML), 1 01/01/2022 145.67 2256.81 11/09/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409553414 Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10 07/01/2022 12.49 137.35 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409491614 Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10 07/01/2022 16.17 177.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409490014 Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10 07/01/2022 16.13 177.39 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409663714 Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10 07/01/2022 11.91 131.01 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409488850 SODIUM CHLORIDE (0.9 % sodium chloride), 0.9 %, VIAL (ML), 1 01/01/2022 6.38 70.15 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409488812 SODIUM CHLORIDE (0.9 % sodium chloride), 0.9 %, VIAL (ML), 1 01/01/2022 4.15 45.65 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409196612 SODIUM CHLORIDE (bacteriostatic sodium chloride), 0.9 %, VIAL (ML), 1 01/01/2022 3.98 43.80 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409114102 SODIUM CHLORIDE (sodium chloride), 4 mEq/mL, VIAL (ML), 1 01/01/2022 0.96 96.88 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409488812 Sodium Chloride Injection Rx, 0.9% (10 mL) Single Dose LifeShield™ Plastic Fliptop Vial, 25 07/01/2022 4.57 50.22 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409710167 Sodium Chloride Injection Rx, 0.9% (100 mL) ADD-Vantage™ Flexible Container, 50 07/01/2022 13.80 151.83 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409710102 Sodium Chloride Injection Rx, 0.9% (250 mL) ADD-Vantage™ Flexible Container, 24 07/01/2022 8.73 96.05 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409710166 Sodium Chloride Injection Rx, 0.9% (50 mL) ADD-Vantage™ Flexible Container, 50 07/01/2022 13.98 153.74 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 09/30/2022 00409488850 Sodium Chloride Injection Rx, 0.9% (50 mL) Single Dose Plastic Fliptop Vial, 25 07/01/2022 7.02 77.17 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00409666075 SODIUM CHLORIDE, 2.5 mEq/mL, Vial, 40 01/01/2022 4.93 39.86 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009082501 SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, Vial, 1 01/01/2022 2.28 13.69 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009000501 SOLU-CORTEF (hydrocortisone sodium succinate/PF), 1,000 mg/8 mL, Vial, 1 01/01/2022 22.83 136.98 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009001103 SOLU-CORTEF (hydrocortisone sodium succinate/PF), 100 mg / 2 mL, Vial, 1 01/01/2022 3.08 18.50 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009001104 SOLU-CORTEF (hydrocortisone sodium succinate/PF), 100 mg/2 mL, Vial, 1 01/01/2022 77.13 462.76 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009001305 SOLU-CORTEF (hydrocortisone sodium succinate/PF), 250 mg / 2 mL, Vial, 1 01/01/2022 5.71 34.24 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009001306 SOLU-CORTEF (hydrocortisone sodium succinate/PF), 250 mg/2 mL, Vial, 1 01/01/2022 142.66 855.96 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00009001612 SOLU-CORTEF (hydrocortisone sodium succinate/PF), 500 mg/4 mL, Vial, 1 01/01/2022 11.42 68.50 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069055038 SUTENT (sunitinib malate), 12.5 mg, CAPSULE, 1 01/01/2022 311.23 5969.88 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069077038 SUTENT (sunitinib malate), 25 mg, CAPSULE, 1 01/01/2022 622.45 11939.77 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069083038 SUTENT (sunitinib malate), 37.5 mg, CAPSULE, 1 01/01/2022 933.68 17909.66 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069098038 SUTENT (sunitinib malate), 50 mg, CAPSULE, 1 01/01/2022 1083.60 20785.45 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00005010010 TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg / 0.5 mL, SYRINGE (ML), 1 01/01/2022 108.05 1674.04 10/01/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on regulatory exclusivity.
Rx0000006 Pfizer 03/31/2022 00005010005 TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, SYRINGE (ML), 1 01/01/2022 54.02 837.02 10/01/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on regulatory exclusivity.
Rx0000006 Pfizer 09/30/2022 00409963305 Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr™ Plastic Syringe, 10 07/01/2022 55.50 610.48 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069019730 VIZIMPRO (dacomitinib), 15 mg, TABLET, 1 01/01/2022 751.91 14422.91 08/01/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application.
Rx0000006 Pfizer 03/31/2022 00069119830 VIZIMPRO (dacomitinib), 30 mg, TABLET, 1 01/01/2022 751.91 14422.91 08/01/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application.
Rx0000006 Pfizer 03/31/2022 00069229930 VIZIMPRO (dacomitinib), 45 mg, TABLET, 1 01/01/2022 751.91 14422.91 08/01/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application.
Rx0000006 Pfizer 03/31/2022 00069814120 XALKORI (crizotinib), 200 mg, CAPSULE, 1 01/01/2022 1022.26 19608.87 10/08/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069814020 XALKORI (crizotinib), 250 mg, CAPSULE, 1 01/01/2022 1022.26 19608.87 10/08/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069100201 XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1 01/01/2022 271.18 5201.67 12/08/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069100101 XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1 01/01/2022 271.18 5201.67 12/08/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006 Pfizer 03/31/2022 00069050130 XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1 01/01/2022 271.18 5201.67 12/08/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121050400 Acetaminophen & Codeine Phosphate CV 120mg/12mg, 5mL 100/cs 03/15/2022 111.30 234.97 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121100800 Acetaminophen & Codeine Phosphate CV 300mg/30mg, 12.5mL 100/cs 03/15/2022 131.22 277.02 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121064610 AMANTADINE HCL50 mg/5 mL, 10 TRAY in 1 CASE (0121-0646-10) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE 03/15/2022 106.95 320.85 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121097800 Diphenhydramine HCL 12.5mg/5mL (10mL), 10 TRAY in 1 CASE (0121-0978-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE (0121-0978-10) 03/15/2022 62.66 375.95 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121048900 Diphenhydramine HCL 12.5mg/5mL, 10 TRAY in 1 CASE (0121-0489-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-0489-05) 03/15/2022 80.60 379.13 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121065416 FLUPHENAZINE HCL2.5 mg/5 mL, 473 mL in 1 BOTTLE (0121-0654-16) 03/15/2022 66.36 255.96 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121157610 METOCLOPRAMIDE HCL10 mg/10 mL, 10 TRAY in 1 CASE (0121-1576-10) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE 03/15/2022 166.91 352.36 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121119000 Sodium Citrate/ Citric Acid 30 mL, 10 TRAY in 1 CASE (0121-1190-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 30 mL in 1 CUP, UNIT-DOSE (0121-1190-30) 03/15/2022 106.51 461.55 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121059500 Sodium Citrate/ Citric Acid, 10 TRAY in 1 CASE (0121-0595-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 15 mL in 1 CUP, UNIT-DOSE (0121-0595-15) 03/15/2022 98.15 425.33 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121085340 Sulfamethoxazole and Trimethoprim Oral Solution USP, 4 TRAY in 1 CASE (0121-0853-40) > 10 CUP, UNIT-DOSE in 1 TRAY > 20 mL in 1 CUP, UNIT-DOSE (0121-0853-20) 03/15/2022 91.77 397.68 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121135000 Valproic Acid Oral Solution, 10 TRAY in 1 CASE (0121-1350-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE (0121-1350-10) 03/15/2022 75.95 160.34 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121467500 Valproic Acid Oral Solution, 10 TRAY in 1 CASE (0121-4675-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-4675-05) 03/15/2022 41.63 87.88 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000135 Pharmaceutical Associates, Inc 03/31/2022 00121467540 Valproic Acid Oral Solution, 4 TRAY in 1 CASE (0121-4675-40) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-4675-05) 03/15/2022 26.61 56.18 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962014012 Imbruvica 120 Oral Capsule 140 MG 01/14/2022 1472.13 21365.82 10/24/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962007028 Imbruvica 28 Oral Capsule 70 MG 01/14/2022 1030.49 14956.08 10/24/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962001428 Imbruvica 28 Oral Tablet 140 MG 01/14/2022 1030.49 14956.08 03/03/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962028028 Imbruvica 28 Oral Tablet 280 MG 01/14/2022 1030.49 14956.08 03/03/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962042028 Imbruvica 28 Oral Tablet 420 MG 01/14/2022 1030.49 14956.08 03/03/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962056028 Imbruvica 28 Oral Tablet 560 MG 01/14/2022 1030.49 14956.08 03/03/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000237 Pharmacyclics an AbbVie Company 03/31/2022 57962014009 Imbruvica 90 Oral Capsule 140 MG 01/14/2022 1104.10 16024.37 10/24/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000289 Piramal Critical Care 09/30/2022 66794001725 Isoflurane Inhallation Solution 250 ml 1 bottle 07/01/2022 10.00 40.00 None Non-innovator Multiple Source Drug None 1 None 1 The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs None None None None None None None None None None None None
Rx0000289 Piramal Critical Care 09/30/2022 66794001925 Terrell Isoflurane Inhallation Solution 250 ml 1 bottle 07/01/2022 10.00 40.00 None Non-innovator Multiple Source Drug None 1 None 1 The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs None None None None None None None None None None None None
Rx0000347 Primus Pharmaceuticals Inc 12/31/2022 68040071338 IMPOYZ® External Cream; Clobetasol propionate 0.025%; Cream; 100g 11/21/2022 115.00 1350.00 08/31/2030 Single Source Drug None 1 None 1 N/A None None None None None None None None None None None None
Rx0000347 Primus Pharmaceuticals Inc 12/31/2022 68040071428 Sernivo® Spray; Betamethasone dipropionate 0.05%; Emulsion Spray; 120g in 1 bottle 11/21/2022 92.50 1090.00 08/31/2030 Single Source Drug None 1 None 1 N/A None 03/01/2021 Encore Dermatology None 1 None 997.50 902.95 2017 859.95 None None
Rx0000236 PTC Therapeutics, Inc 03/31/2022 52856050203 EMFLAZA (deflazacort) 18mg tabs/ 30 ct 01/17/2022 528.44 6465.94 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 3925.00 0.00 2017 3925.00 None Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 09/30/2022 52856050203 EMFLAZA (deflazacort) 18mg tabs/30 ct 07/18/2022 607.79 7073.73 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 3925.00 0.00 2017 3925.00 None Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 03/31/2022 52856050522 EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE 01/17/2022 386.80 4732.90 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 2873.00 0.00 2017 2873.00 None Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 09/30/2022 52856050522 EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE 07/18/2022 444.89 5177.79 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 2873.00 0.00 2017 2873.00 None Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 03/31/2022 52856050303 EMFLAZA (deflazacort) 30mg tabs/ 30 ct 01/17/2022 880.78 10777.11 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 6542.00 0.00 2017 6542.00 None Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 09/30/2022 52856050303 EMFLAZA (deflazacort) 30mg tabs/30 ct 07/18/2022 1013.05 11790.16 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 6542.00 0.00 2017 6542.00 None Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 03/31/2022 52856050403 EMFLAZA (deflazacort) 36mg tabs/ 30 ct 01/17/2022 1019.60 12475.73 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 7290.00 0.00 2017 7290.00 None Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 09/30/2022 52856050403 EMFLAZA (deflazacort) 36mg tabs/30 ct 07/18/2022 1172.72 13648.45 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 7290.00 0.00 2017 7290.00 None Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 03/31/2022 52856050101 EMFLAZA (deflazacort) 6mg tabs/100 ct 01/17/2022 587.13 7184.19 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 4361.00 0.00 2017 4361.00 None Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236 PTC Therapeutics, Inc 09/30/2022 52856050101 EMFLAZA (deflazacort) 6mg tabs/100 ct 07/18/2022 675.31 7859.50 None Single Source Drug None 1 None 1 None 1 04/01/2017 Marathon Pharmaceuticals 140000000 None None 4361.00 0.00 2017 4361.00 None Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000220 Puma Biotechnology, Inc. 03/31/2022 70437024018 Nerlynx Oral Tablet 40 mg, 180 tablet package 01/10/2022 900.00 19275.00 07/18/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000342 PureTek Corporation 06/30/2022 59088017854 Pretrate, prenatal/ postnatal multivitamin, caplets, 30ct, Vitamin A 1500mcg, Vitamin C 120mg, Vitamin D3 20mcg, Vitamin E 30mg, Thiamin 3mg, Riboflavin 3.4mg, Niacin 20mg, Vitamin B6 50mg, Folate 1700mcg DFE, Vitamin B12 10mcg, Choline 55mg, Calcium 200mg, Iron 27mg, Iodine 150mcg, Magnesium 200mg, Zinc 25mg, Selenium 70mcg, Manganese 2.6mg, Chromium 45mcg, Molybdenum 50mcg 06/30/2022 220.00 1680.00 None Single Source Drug 807 None Raw material and labor None None 1 None None None None None None None None None None None